Latest news:

Follicum expands patent portfolio: First diabetes patent published and promising experimental data supports new patent application

Lund, Sweden, November 12, 2018. Follicum AB (“Follicum” or “the Company”) today announced that the company’s diabetes project is progressing according to plan and that the company has submitted a new patent application. Experimental studies show that the company’s new optimized peptides exert a protective and preservative effect on beta cells exposed to high glucose […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Hair growth

Our drug candidate FOL-005 has, in clinical trials, demonstrated increased hair growth on healthy individuals

Read more

Diabetes

Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more

Investors

We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more

Press

News

Events